SIGA Technologies reported financial results for the quarter ended June 30, 2026. The company generated $37.9 million in product sales and $41.0 million in total revenues, compared to $79.1 million and $81.1 million respectively in the prior year period. Net income was $12.5 million, or $0.17 per diluted share, down from $35.5 million and $0.49 per share a year ago. The company delivered approximately $24 million of IV TPOXX to the U.S. strategic national stockpile and $13 million of oral TPOXX to international customers. These deliveries completed the last procurement order under the 19C contract with BARDA. SIGA is a commercial-stage pharmaceutical company focused on developing innovative medicines to treat and prevent infectious diseases.